Managing Director of Hatteras Discovery and Venture Partner at Hatteras Venture Partners
Vice President for Research at UT Health Science Center at San Antonio
Head of global research and development at Life Technologies
President and CEO of the Central Indiana Corporate Partnership
Title I of the JOBS Act, which was signed into law in April of this year, represents a sea change in (1) the US initial public offering process and (2) the regulatory regime applicable to almost all newly public companies.
Mark Roeder, Global Co-chair of the Life Sciences Industry Group of Latham & Watkins, will moderate a panel with Joel Trotter, one of two lawyers who served on the IPO Task Force—the group whose recommendations gave rise to Title I of the JOBS Act — Scott Morrison, US Life Sciences Director for E&Y, and Brian Cuneo, an attorney in Latham & Watkins’ Life Sciences Group. The panelists will discuss the effect of the JOBS Act on life sciences companies considering a US IPO, their underwriters, sponsors and financial advisors. The panelists will also cover lessons learned during the first wave of IPOs under the JOBS Act and industry-specific trends that are emerging as a result of these dramatic changes to the IPO framework and the landscape for newly public companies.
Mark Roeder, Global Co-chair Life Sciences Industry Group, Latham & Watkins
Joel Trotter, Partner, Latham & Watkins
Scott Morrison, US Life Sciences Director, Ernst & Young
Brian Cuneo, Associate, Latham & Watkins
The program is free; register here.